1. Home
  2. MRT vs RCEL Comparison

MRT vs RCEL Comparison

Compare MRT & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marti Technologies Inc.

MRT

Marti Technologies Inc.

HOLD

Current Price

$2.00

Market Cap

164.5M

ML Signal

HOLD

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$3.69

Market Cap

132.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRT
RCEL
Founded
2018
N/A
Country
Turkey
United States
Employees
N/A
226
Industry
Rental/Leasing Companies
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
164.5M
132.0M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
MRT
RCEL
Price
$2.00
$3.69
Analyst Decision
Strong Buy
Buy
Analyst Count
2
5
Target Price
$6.00
$7.88
AVG Volume (30 Days)
18.6K
158.6K
Earning Date
08-08-2018
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$84.47
$17.17
Revenue Next Year
$94.45
$49.82
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.97
$3.22
52 Week High
$3.70
$10.28

Technical Indicators

Market Signals
Indicator
MRT
RCEL
Relative Strength Index (RSI) 42.42 37.26
Support Level $1.98 $3.33
Resistance Level $2.15 $4.09
Average True Range (ATR) 0.05 0.24
MACD -0.00 -0.06
Stochastic Oscillator 0.00 14.40

Price Performance

Historical Comparison
MRT
RCEL

About MRT Marti Technologies Inc.

Marti Technologies Inc is a mobility app, offering multiple transportation services to its riders. Marti operates a ride-hailing service that matches riders with car, motorcycle, and taxi drivers, and operates a large fleet of rental e-mopeds, e-bikes, and e-scooters. All of Marti's offerings are serviced by proprietary software systems and IoT infrastructure.

About RCEL Avita Medical Inc.

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: